Thyroid nodule resident survival guide: Difference between revisions

Jump to navigation Jump to search
(Created page with "<div style="width: 85%;"> __NOTOC__ '''For Thyroid nodule click here.''' {{CMG}}; {{AE}} {{MIR}} {| class="infobox" style="margin: 0 0 0 0; border: 0; floa...")
 
No edit summary
 
(40 intermediate revisions by 4 users not shown)
Line 1: Line 1:
<div style="width: 85%;">
<div style="width: 85%;">
__NOTOC__
'''For Thyroid nodule click [[Thyroid nodule|here]].'''


{{CMG}}; {{AE}} {{MIR}}
{{CMG}}; {{AE}} {{MIR}}
{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 10px 10px 10px 10px;" cellpadding="0" cellspacing="0";
{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 100px; background: #A8A8A8; position: fixed; top: 250px; right: 21px; border-radius: 10px 10px 10px 10px;" cellpadding="0" cellspacing="0" ;
|-
|-
! style="padding: 0 5px; font-size: 85%; background: #A8A8A8" align=center| {{fontcolor|#2B3B44|Gastroentritis Resident Survival Guide Microchapters}}
! style="padding: 0 5px; font-size: 85%; background: #A8A8A8" align="center" | {{fontcolor|#2B3B44|Thyroid nodule Resident Survival Guide Microchapters}}
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#Overview|Overview]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[{{PAGENAME}}#Overview|Overview]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#Classification|Classification]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[{{PAGENAME}}#Classification|Classification]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#Causes|Causes]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[{{PAGENAME}}#Causes|Causes]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#FIRE: Focused Initial Rapid Evaluation|FIRE]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[{{PAGENAME}}#FIRE: Focused Initial Rapid Evaluation|FIRE]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#Diagnosis|Diagnosis]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[{{PAGENAME}}#Diagnosis|Diagnosis]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#Treatment|Treatment]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[{{PAGENAME}}#Treatment|Treatment]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#Do's|Do's]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[{{PAGENAME}}#Do's|Do's]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#Don'ts|Don'ts]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align="left" | [[{{PAGENAME}}#Don'ts|Don'ts]]
|}
|}
== Overview ==
Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. The American Thyroid Association has published guidelines for the management of thyroid nodules, which were updated in 2015. The major causes of thyroid nodule development include, [[Multinodular goiter|multinodular (sporadic) goiter]], [[Hashimoto's thyroiditis]], [[cysts]], macrofollicular/microfollicular adenomas, childhood [[radioiodine]] exposure, [[familial history]], and [[gene]] [[mutations]]. [[Neck masses]] can be mistaken for thyroid nodules. The most important [[neck masses]] that can be mistaken with thyroid nodules include, [[Thyroglossal cyst|thyroglossal]] duct cyst, [[parathyroid cancer]], [[Parathyroid gland|parathyroid]] cyst, and [[branchial cleft cyst]]. While the diagnosis of a thyroid nodule is established, thyroid nodule should be differentiated based on benign or [[malignant]] features and the type of nodule. Common [[risk factors]] associated with thyroid nodules include, older age, [[iodine deficiency]], previous history of [[iodine deficiency]] and [[hypothyroidism]], living in iodine deficient areas, family history of [[Autoimmune disease|autoimmune diseases,]] multiparity, and [[smoking]]. A solitary thyroid nodule may become [[symptomatic]] if it grows rapidly due to [[hemorrhage]] or [[malignancies]], invades [[Laryngeal nerve|laryngeal nerves]], compressing nearby structures, and secretory nodules that produce [[TSH]]. Thyroid nodules may be a manifestation of [[thyroid cancer]], that usually develops in the 6th decade of life, and start with [[symptoms]] such as [[weight loss]], [[fatigue]], and [[hoarseness]]. Without treatment, the patient with [[benign]] n<nowiki/>odules may remain [[asymptomatic]], while the patients with [[thyroid]] [[neoplasm]] may develop distant [[metastasis]], which may eventually lead to death. The most common complications of thyroid nodules are [[hoarseness]], [[horner's syndrome]], nodule rupture, needle track seeding, [[hemorrhage]]/[[hematoma]], [[dysphagia]], [[upper airway obstruction]], [[pain]], [[skin]] burn, [[Vasovagal Syncope|vasovagal reaction]], [[hypothyroidism]], transient [[thyrotoxicosis]], [[anaphylactic reaction]], [[thromboembolism]], and [[pneumothorax]]. Physical examination should focus on the [[thyroid gland]] and the lateral and central [[neck]] and should assess for [[supraclavicular]] and [[submandibular]] [[adenopathy]]. In case of active hot thyroid nodules that produce [[thyroid hormones]], [[Antithyroid agent|antithyroid drugs]] should be administered, that include [[beta-blockers]], antithyroid drugs ([[methimazole]],[[carbimazole]],[[propylthiouracil]]), [[Iodine-131|radioactive iodine]], and [[thyroidectomy]]. If the nodule excision treatment ([[lobectomy]], [[isthmectomy]], and total [[thyroidectomy]]) is not curative, then treatment with postoperative [[radioactive iodine]] ([[RAI1|RAI]]) remnant ablation and recombinant human TSH–mediated therapy is recommended. Surgical management of thyroid nodule is performed in case of non-diagnostic or suspicious biopsy, for removal of primary [[thyroid cancer]] or for [[thyroid cancer]] staging for [[radioactive]] ablation and [[serum]] [[thyroglobulin]] monitoring. [[Primary prevention]] of thyroid nodule is aimed at prevention of [[thyroid cancer]]. Avoidance of exposure to [[radiation]] and monitoring the population with an increased risk of development of a [[malignant]] thyroid nodule play major roles in [[primary prevention]]. [[Secondary prevention]] of thyroid nodules focuses on [[Prevention (medical)|prevention]] of recurrence of nodules. Different prevention strategies may be used depending upon whether the nodule is [[benign]] or [[malignant]]. In case of  a malignant nodule, the major focus is on the [[Prevention (medical)|prevention]] of recurrence after removal of a primary nodule. Post-operative periodic monitoring with [[serum]] [[thyroglobulin]] levels, [[Radioactive iodine uptake|radioactive iodine scanning]], [[neck]] [[ultrasound]] and [[Thyroid-stimulating hormone|thyroid stimulating hormone]] ([[TSH]]) may decrease the chances of recurrence.
== Classification ==
The various classification systems for thyroid nodules can be summarized as follows:
{{familytree/start}}
{{familytree | | | | | | | | B01 | | | | |B01=Thyroid nodule classification}}
{{familytree | | |,|-|-|-|-|-|+|-|-|-|-|-|.| }}
{{familytree | | C01 | | | | |!| | | | | C03 |C01= '''Bethesda classification system''' |C03= '''TIRAD classification system'''}}
{{familytree | | |!| | | | | |!| | | | | |!| }}
{{familytree | | C01 | | | | |!| | | | | C03 |C01= Based on thyroid [[cytopathology]] |C03= Based on [[Ultrasound|sonographic]] features}}
{{familytree | | |!| | | | | |!| | | | | |!| }}
{{familytree | boxstyle=text-align: left; | | C01 | | | | |!| | | | | C03 |C01= •[[Benign]] <br> •Nondiagnostic or Unsatisfactory <br> •Follicular lesion of undetermined significance <br> •[[Atypia]] of undetermined significance <br> •Follicular neoplasm <br> •Suspicious for a follicular neoplasm <br> •[[Malignant]] <br> | C03= •TIRADS 1=Normal [[thyroid gland]] <br> •TIRADS 2=[[Benign]] lesions <br> •TIRADS 3=Probably [[benign]] lesions <br> •TIRADS 4= Contain 1-4 suspicious features <br> •TIRADS 5=Contain all five suspicious features <br> •TIRADS 6=Biopsy proven [[malignancy]]}}
{{familytree | | | | | | | | C02 | | | | | | | C02= Differentiated and anaplastic thyroid carcinoma }}
{{familytree | | | | |,|-|-|-|^|-|-|-|.| | | }}
{{familytree | | | | F01 | | | | | | F02 | | | | F01 = '''TNM staging AJCC UICC 2017''' |  F02 = '''Classification based on their origin'''}}
{{familytree | | | | |!| | | | | |,|-|^|-|.| | | | }}
{{familytree | boxstyle=text-align: left; | | | | F01 | | | X01 | | | | X02 | | | F01 =  •Primary tumor (T) <br> •Regional [[lymph node|lymph nodes]] (N) <br> •Distant [[metastasis]] (M) | X01 = Nonmedullary (epithelial) [[thyroid cancers]] (NMTCs) <br> •Papillary cell tumors <br> •Follicular tumors <br> •Hurthle cell tumors <br> •Anaplastic tumors | X02 = Medullary thyroid cancers }}
{{familytree/end}}
== Causes ==
=== Life-threatening causes ===
The most important [[genes]] which can lead to [[thyroid cancer]] include:<ref name="pmid205107112">{{cite journal |vauthors=Bomeli SR, LeBeau SO, Ferris RL |title=Evaluation of a thyroid nodule |journal=Otolaryngol. Clin. North Am. |volume=43 |issue=2 |pages=229–38, vii |year=2010 |pmid=20510711 |pmc=2879398 |doi=10.1016/j.otc.2010.01.002 |url=}}</ref><ref name="pmid261807652">{{cite journal |vauthors=Jena A, Patnayak R, Prakash J, Sachan A, Suresh V, Lakshmi AY |title=Malignancy in solitary thyroid nodule: A clinicoradiopathological evaluation |journal=Indian J Endocrinol Metab |volume=19 |issue=4 |pages=498–503 |year=2015 |pmid=26180765 |pmc=4481656 |doi=10.4103/2230-8210.159056 |url=}}</ref><ref name="pmid206939482">{{cite journal |vauthors=Chibishev A, Simonovska N, Shikole A |title=Post-corrosive injuries of upper gastrointestinal tract |journal=Prilozi |volume=31 |issue=1 |pages=297–316 |year=2010 |pmid=20693948 |doi= |url=}}</ref>
* N&H [[Ras oncogene|ras]]
* [[RET gene|RET]]
* Gsp
* [[C-MET]] (α and β subunit)
* [[TRK]]
* EGF / [[EGFR|EGF-R]]
* [[P53]]
Causes of [[malignant]] nodule [[mutations]]:
* Childhood [[radioiodine]] exposure
* [[Family history|Familial history]]
=== Common causes ===
The most important causes of thyroid nodule development include:<ref name="pmid20510711">{{cite journal |vauthors=Bomeli SR, LeBeau SO, Ferris RL |title=Evaluation of a thyroid nodule |journal=Otolaryngol. Clin. North Am. |volume=43 |issue=2 |pages=229–38, vii |year=2010 |pmid=20510711 |pmc=2879398 |doi=10.1016/j.otc.2010.01.002 |url=}}</ref><ref name="pmid26180765">{{cite journal |vauthors=Jena A, Patnayak R, Prakash J, Sachan A, Suresh V, Lakshmi AY |title=Malignancy in solitary thyroid nodule: A clinicoradiopathological evaluation |journal=Indian J Endocrinol Metab |volume=19 |issue=4 |pages=498–503 |year=2015 |pmid=26180765 |pmc=4481656 |doi=10.4103/2230-8210.159056 |url=}}</ref><ref name="pmid20693948">{{cite journal |vauthors=Chibishev A, Simonovska N, Shikole A |title=Post-corrosive injuries of upper gastrointestinal tract |journal=Prilozi |volume=31 |issue=1 |pages=297–316 |year=2010 |pmid=20693948 |doi= |url=}}</ref>
* Causes of [[benign]] thyroid nodule:
** [[Goiter|Multinodular (sporadic) goiter ("colloid adenoma")]]
** [[Hashimoto thyroiditis|Hashimoto's (chronic lymphocytic) thyroiditis]]
** [[Cysts]] (colloid, simple, or [[hemorrhagic]])
** Follicular [[adenomas]]
** Macrofollicular [[adenomas]]
** Microfollicular or cellular [[adenomas]]
** [[Hurthle cells|Hürthle cell]] ([[oxyphil cell]]) [[adenomas]]
** Macro- or microfollicular patterns
== A Complete Diagnostic Approach and Management ==
<span style="font-size:85%">'''Abbreviations:'''
'''TSH:''' [[Thyroid stimulating hormone]], '''FNA:''' [[FNA|Fine needle aspiration]], '''FLUS:''' Follicular lesion of undetermined significance, '''AUS:''' Atypia of undetermined significance.
</span>
<br>
<small>
{| align="center"
|-
|
{{familytree/start |summary=Thyroid Nodule Evaluation Algorithm}}
{{familytree | | | | | | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | A01= '''Thyroid nodule found clinically or incidentally'''}}
{{familytree | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | | | | | | | B01 | | | | | | | | | | | | | B01=''' TSH '''}}
{{familytree | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | |,|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|.| | | }}
{{familytree | | | | | | | | | C01 | | | | | | | | | | | | | | | | | | C02 | C01 = '''Normal or elevated''' | C02 = '''Subnormal'''}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | |!| | | | | |}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | C01 | | | | | | C01 = '''Radionuclide thyroid scan'''}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | |,|-|-|-|-|^|-|-|-|-|.| |}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | C01 | | | | | | | | C02 | | | C01 = Nodule not up taking the radionuclide <br>'''Cold nodule''' <br> Nodule is non-functional | C02 = Nodule up taking the radionuclide '''Hot nodule''' <br> Nodule is functional}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | |!| | | | | | | | | |!| | | | }}
{{familytree | | | | | | | | | |`|-|-|-|-|-|-|-|-|-|-|-|-|-| C01 | | | | | | | | C02 | | | | C01 = Ultrasound evaluation | C02 = Check thyroid hormones<br> '''Free T4 and T3 check'''}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | |!| }}
{{familytree | | | | | | | | | | | | | | | | | | |,|-|-|-|-|-|^|-|.| | | | | |,|-|^|-|.| }}
{{familytree | | | | | | | | | | | | | | | | | | C01 | | | | | | C02 | | | | C03 | | C04 | C01 = Meets the criteria <br> | C02 = Doesn't meet criteria | C03 = Normal <br> '''Subclinical hypothyroidism''' | C04 = Elevated <br> '''Thyroid adenoma''' <br> ''' Hyperthyroidism'''}}
{{familytree | | | | | | | | | | | | | | | | | | |!| | | | | | | |!| | | | | |!| | | |!| | | }}
{{familytree | | | | | | | | | | | | | | |,|-|-|-|+|-|-|-|-|.| | |`|-| C04 |-|'| | | B04 | C04 = '''Monitoring''' | B04 = '''Treat hyperthyroidism''' }}
{{familytree | | | | | | | | | | | | | A01 | | A02 | | | | | A03 | | | | | | | A01 = Cystic nodule | A02 = Spongiform nodule | A03 = Solid nodule }}
{{familytree | | | | | | | | | | | | | |!| | | |!| | | |,|-|-|+|-|-|.| | | }}
{{familytree | | | | | | | | | | | | | |`| D01 |'| | A01 | | A02 | | A03 | | | | A01 = Hyperechoic or isoechoic or partially cystic nodule with eccentric solid areas | A03 = Hypoechoic solid nodule or solid hypoechoic component of a partially cystic nodule WITH one or more of the following features:<br> Irregular margins <br>  Microcalcifications <br> Taller than wide shape <br> Rim calcifications with small extrusive soft tissue component <br> Evidence of extrathyroidal extension
| A02 = Hypoechoic solid nodule with smooth margins WITHOUT the following features: <br> Microcalcifications<br>  Extrathyroidal extension <br> Taller than wider shape | D01 = Without malignant features }}
{{familytree | | | | | | | | | | | | | | | |!| | | | |!| | | |!| | | |!| | | | }}
{{familytree | | | | | | | | | | | | | | | S01 | | | A01 | | A02 | | A03 | | | | A01 = '''Low suspicion for malignancy''' | A02 = '''Intermediate suspicion of malignancy''' | A03 = '''High  suspicion of malignancy''' | S01 = '''Very low suspicion of malignncy''' }}
{{familytree | | | | | | | | | | | | | | | |:| | | | |:| | | |:| | | |:| | }}
{{familytree | | | | | | | | | | | | | | | S01 | | | A01 | | A02 | | A03 | | | | S01 =Estimated risk of malignancy <br> '''<3%''' | A01 = Estimated risk of malignancy <br> '''5 to 10%''' | A02 = Estimated risk of malignancy <br> '''10 to 20%''' | A03 = Estimated risk of malignancy <br> '''>70 to 90%''' }}
{{familytree | | | | | | | | | | | | | | | | |!| | | |!| | | |`|-|v|-|'| | | | | }}
{{familytree | | | | | | | | | | | | | | | | S01 | | A01 | | | | B01 | | | | S01 = FNA if nodule is larger that 2cm | A01 = FNA if nodule is larger that 1.5cm | B01 = FNA if nodule is larger that 1cm}}
{{familytree | | | | | | | | | | | | | | | | |`|-|-|-|^|v|-|-|-|-|'| | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | | | | | C01 = FNA result}}
{{familytree | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | |,|-|-|-|-|-|-|-|-|-|v|-|-|-|-|+|-|-|-|-|v|-|-|-|-|v|-|-|-|-|v|-|-|-|.| }}
{{familytree | | | | | | A01 | | | | | | | | A02 | | | A03 | | | A04 | | | A05 | | | A06 | | A07 | | | A01 = '''Follicular neoplasm''' | A02 = '''FLUS''' | A03 = '''AUS''' | A04 = '''Benign''' | A05 = '''Suspicious for malignancy''' | A06 = '''Papillary thyroid carcinoma''' | A07 = '''Nondiagnostic'''}}
{{familytree | | | | | | |!| | | | | | | | | |!| | | | |!| | | | |!| | | | |!| | | | |!| | | |!| | | }}
{{familytree | | | | | | |!| | | | | | | | | |`|-|v|-|-|'| | | | F01 | | | |`|-|-|v|-|'| | | F02 | | | | F01 = '''Repeat Ultrasound''' every 1-2 year <br> If growth more>20% or suspicious ultrasound results, consider '''FNA''' again | F02 = '''Repeat FNA with ultrasound guidance''' }}
{{familytree | | | | | | |!| | | | | | | | | | | S01 | | | | | |!|!|!| | | | | | S02 | | | | | | | | S01 = '''Repeat FNA''' in 2-3 months | S02 = '''Total thyroidectomy''' }}
{{familytree | | | | | | |!| | | | | | |,|-|-|-|-|^|-|-|-|-|.| |!|!|!| | | | | | | | | | | | | | | }}
{{familytree | | | | | | |!| | | | | | A01 | | | | | | | | A02 |'|!|!| | | | | | | | | | | | | | | | A01 = AUS <br> FLUS | A02 = '''Benign'''}}
{{familytree | | | | | | |`|-|-|-|v|-|-|'| | | | | | | | | | | | |!|!| | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | |!| | | | | | | | | | | | | | | |!|!| | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | |,|-|^|-|-|.| | | | | | | | | | | | |!|!| | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | R01 | | | R02 |-|-|-|-|-|-|-|-|-|-|-|'|!| | | | | | | | | | | | | | | | | R01 = '''Cold''', non-functional nodule | R02 = '''Hot''', functional, benign nodule}}
{{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | R01 | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | R01 = '''Thyroid lobectomy''' considering ultrasound results <br> AND <br> '''Molecular diagnostic testing''' <br> *Gene expression classifier <br> * Mutational analysis}}
{{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | }}
{{familytree | | | | | |,|-|-|^|-|-|-|-|-|-|.| | | | | | | | | | | |!| | | | | | | | | | | | | | | }}
{{familytree | | | | | W01 | | | | | | | | W02 |-|-|-|-|-|-|-|-|-|-|'| | | | | | | | | | | | | | | | | | | | | W01 = '''Suspicious to malignancy''' | W02 = '''Benign''' }}
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | A01 = '''Lobectomy''' <br> OR <br> '''Total thyroidectomy''' based on the ultrasound evaluation }}
{{familytree/end}}
|}
== Do's ==
'''Thyroglobulin level monitoring'''
*Order serum [[thyroglobulin]] periodically during follow-up of patients with differentiated [[thyroid cancer]] who have undergone less than total [[thyroidectomy]]
*Order serum [[thyroglobulin]] periodically during follow-up of patients with differentiated [[thyroid cancer]] who have had a total [[thyroidectomy]] but not [[Iodine-131|radioactive iodine]] ablation
'''Cervical ultrasound'''
*Perform [[neck]] [[ultrasound]] to evaluate [[thyroid]] 6–12 months following surgery
'''18FDG-PET scanning'''
*Consider 18FDG-PET scanning in high-risk differentiated [[thyroid cancer]] patients with elevated serum [[thyroglobulin]] (generally >10 ng/mL) and negative [[Iodine-131|radioactive iodine]] imaging
'''CT scans'''
*Order [[chest]] [[Computed tomography|CT scan]] with or without intravenous [[Contrast medium|contrast]] in high-risk differentiated [[thyroid cancer]] patients with elevated serum [[thyroglobulin]] (generally >10 ng/mL) or rising [[thyroglobulin]] [[antibodies]] with or without negative [[Iodine-131|radioactive iodine]] imaging
'''TSH range'''
*Maintain serum [[Thyroid-stimulating hormone|TSH]] below 0.1 mU/L in patients with a structural incomplete response to therapy, indefinitely in the absence of specific contraindications
*Maintain serum [[Thyroid-stimulating hormone|TSH]] between 0.5-2 mU/L in patients with an excellent or indeterminate response to therapy, especially those at low risk for recurrence
'''Surgery for nodal disease'''
*Perform surgery in patients with clinically apparent, macroscopic nodal disease
*Perform therapeutic compartmental central and/or lateral [[neck dissection]] in a previously operated [[Compartment (anatomy)|compartment]], in patients with [[biopsy]]-proven persistent or recurrent disease for central [[neck]] nodes ≥8 mm and lateral [[neck]] nodes ≥10 mm
*Perform compartmental surgery
*Perform combination of surgery and [[Iodine-131|radioactive iodine]] and/or [[External beam radiotherapy|external beam radiation therapy]] (EBRT) in patients with aerodigestive invasive disease
*Order [[complete blood count]] and assessment of renal function before administration of [[Iodine-131|radioactive iodine]]
*Discuss preventive strategies for [[dental caries]] with patients with [[xerostomia]]
'''Radioactive iodine therapy'''
*Order [[pregnancy test]] before [[Iodine-131|radioactive iodine]] administration
*Administer [[Iodine-131|radioactive iodine]] therapy in patients with iodine-avid [[bone metastases]]
*Administer [[Iodine-131|radioactive iodine]] therapy in patients with [[Lung|pulmonary]] micrometastases and every 6-12 months
== Don'ts ==
*Do not administer [[Iodine-131|radioactive iodine]] to [[Pregnancy|pregnant]] women
*Do not administer [[Iodine-131|radioactive iodine]] to [[nursing]] women
*Do not perform surgery with focal “berry-picking” techniques
== References ==
{{Reflist|2}}

Latest revision as of 21:59, 20 November 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Thyroid nodule Resident Survival Guide Microchapters
Overview
Classification
Causes
FIRE
Diagnosis
Treatment
Do's
Don'ts

Overview

Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. The American Thyroid Association has published guidelines for the management of thyroid nodules, which were updated in 2015. The major causes of thyroid nodule development include, multinodular (sporadic) goiterHashimoto's thyroiditiscysts, macrofollicular/microfollicular adenomas, childhood radioiodine exposure, familial history, and gene mutations. Neck masses can be mistaken for thyroid nodules. The most important neck masses that can be mistaken with thyroid nodules include, thyroglossal duct cyst, parathyroid cancer, parathyroid cyst, and branchial cleft cyst. While the diagnosis of a thyroid nodule is established, thyroid nodule should be differentiated based on benign or malignant features and the type of nodule. Common risk factors associated with thyroid nodules include, older age, iodine deficiency, previous history of iodine deficiency and hypothyroidism, living in iodine deficient areas, family history of autoimmune diseases, multiparity, and smoking. A solitary thyroid nodule may become symptomatic if it grows rapidly due to hemorrhage or malignancies, invades laryngeal nerves, compressing nearby structures, and secretory nodules that produce TSH. Thyroid nodules may be a manifestation of thyroid cancer, that usually develops in the 6th decade of life, and start with symptoms such as weight lossfatigue, and hoarseness. Without treatment, the patient with benign nodules may remain asymptomatic, while the patients with thyroid neoplasm may develop distant metastasis, which may eventually lead to death. The most common complications of thyroid nodules are hoarsenesshorner's syndrome, nodule rupture, needle track seeding, hemorrhage/hematomadysphagiaupper airway obstructionpainskin burn, vasovagal reactionhypothyroidism, transient thyrotoxicosisanaphylactic reactionthromboembolism, and pneumothorax. Physical examination should focus on the thyroid gland and the lateral and central neck and should assess for supraclavicular and submandibular adenopathy. In case of active hot thyroid nodules that produce thyroid hormonesantithyroid drugs should be administered, that include beta-blockers, antithyroid drugs (methimazole,carbimazole,propylthiouracil), radioactive iodine, and thyroidectomy. If the nodule excision treatment (lobectomyisthmectomy, and total thyroidectomy) is not curative, then treatment with postoperative radioactive iodine (RAI) remnant ablation and recombinant human TSH–mediated therapy is recommended. Surgical management of thyroid nodule is performed in case of non-diagnostic or suspicious biopsy, for removal of primary thyroid cancer or for thyroid cancer staging for radioactive ablation and serum thyroglobulin monitoring. Primary prevention of thyroid nodule is aimed at prevention of thyroid cancer. Avoidance of exposure to radiation and monitoring the population with an increased risk of development of a malignant thyroid nodule play major roles in primary prevention. Secondary prevention of thyroid nodules focuses on prevention of recurrence of nodules. Different prevention strategies may be used depending upon whether the nodule is benign or malignant. In case of a malignant nodule, the major focus is on the prevention of recurrence after removal of a primary nodule. Post-operative periodic monitoring with serum thyroglobulin levels, radioactive iodine scanning, neck ultrasound and thyroid stimulating hormone (TSH) may decrease the chances of recurrence.

Classification

The various classification systems for thyroid nodules can be summarized as follows:

 
 
 
 
 
 
 
Thyroid nodule classification
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bethesda classification system
 
 
 
 
 
 
 
 
 
 
TIRAD classification system
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on thyroid cytopathology
 
 
 
 
 
 
 
 
 
 
Based on sonographic features
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Benign
•Nondiagnostic or Unsatisfactory
•Follicular lesion of undetermined significance
Atypia of undetermined significance
•Follicular neoplasm
•Suspicious for a follicular neoplasm
Malignant
 
 
 
 
 
 
 
 
 
 
•TIRADS 1=Normal thyroid gland
•TIRADS 2=Benign lesions
•TIRADS 3=Probably benign lesions
•TIRADS 4= Contain 1-4 suspicious features
•TIRADS 5=Contain all five suspicious features
•TIRADS 6=Biopsy proven malignancy
 
 
 
 
 
 
 
Differentiated and anaplastic thyroid carcinoma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TNM staging AJCC UICC 2017
 
 
 
 
 
Classification based on their origin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•Primary tumor (T)
•Regional lymph nodes (N)
•Distant metastasis (M)
 
 
Nonmedullary (epithelial) thyroid cancers (NMTCs)
•Papillary cell tumors
•Follicular tumors
•Hurthle cell tumors
•Anaplastic tumors
 
 
 
Medullary thyroid cancers
 
 

Causes

Life-threatening causes

The most important genes which can lead to thyroid cancer include:[1][2][3]

Causes of malignant nodule mutations:

Common causes

The most important causes of thyroid nodule development include:[4][5][6]

A Complete Diagnostic Approach and Management

Abbreviations: TSH: Thyroid stimulating hormone, FNA: Fine needle aspiration, FLUS: Follicular lesion of undetermined significance, AUS: Atypia of undetermined significance.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thyroid nodule found clinically or incidentally
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TSH
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal or elevated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subnormal
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Radionuclide thyroid scan
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nodule not up taking the radionuclide
Cold nodule
Nodule is non-functional
 
 
 
 
 
 
 
Nodule up taking the radionuclide Hot nodule
Nodule is functional
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ultrasound evaluation
 
 
 
 
 
 
 
Check thyroid hormones
Free T4 and T3 check
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meets the criteria
 
 
 
 
 
Doesn't meet criteria
 
 
 
Normal
Subclinical hypothyroidism
 
Elevated
Thyroid adenoma
Hyperthyroidism
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monitoring
 
 
 
 
 
Treat hyperthyroidism
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cystic nodule
 
Spongiform nodule
 
 
 
 
Solid nodule
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Without malignant features
 
 
 
Hyperechoic or isoechoic or partially cystic nodule with eccentric solid areas
 
Hypoechoic solid nodule with smooth margins WITHOUT the following features:
Microcalcifications
Extrathyroidal extension
Taller than wider shape
 
Hypoechoic solid nodule or solid hypoechoic component of a partially cystic nodule WITH one or more of the following features:
Irregular margins
Microcalcifications
Taller than wide shape
Rim calcifications with small extrusive soft tissue component
Evidence of extrathyroidal extension
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Very low suspicion of malignncy
 
 
Low suspicion for malignancy
 
Intermediate suspicion of malignancy
 
High suspicion of malignancy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estimated risk of malignancy
<3%
 
 
Estimated risk of malignancy
5 to 10%
 
Estimated risk of malignancy
10 to 20%
 
Estimated risk of malignancy
>70 to 90%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FNA if nodule is larger that 2cm
 
FNA if nodule is larger that 1.5cm
 
 
 
FNA if nodule is larger that 1cm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FNA result
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Follicular neoplasm
 
 
 
 
 
 
 
FLUS
 
 
AUS
 
 
Benign
 
 
Suspicious for malignancy
 
 
Papillary thyroid carcinoma
 
Nondiagnostic
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat Ultrasound every 1-2 year
If growth more>20% or suspicious ultrasound results, consider FNA again
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat FNA with ultrasound guidance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat FNA in 2-3 months
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total thyroidectomy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUS
FLUS
 
 
 
 
 
 
 
Benign
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cold, non-functional nodule
 
 
Hot, functional, benign nodule
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thyroid lobectomy considering ultrasound results
AND
Molecular diagnostic testing
*Gene expression classifier
* Mutational analysis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suspicious to malignancy
 
 
 
 
 
 
 
Benign
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lobectomy
OR
Total thyroidectomy based on the ultrasound evaluation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Do's

Thyroglobulin level monitoring

Cervical ultrasound

18FDG-PET scanning

CT scans

TSH range

  • Maintain serum TSH below 0.1 mU/L in patients with a structural incomplete response to therapy, indefinitely in the absence of specific contraindications
  • Maintain serum TSH between 0.5-2 mU/L in patients with an excellent or indeterminate response to therapy, especially those at low risk for recurrence

Surgery for nodal disease

Radioactive iodine therapy

Don'ts

References

  1. Bomeli SR, LeBeau SO, Ferris RL (2010). "Evaluation of a thyroid nodule". Otolaryngol. Clin. North Am. 43 (2): 229–38, vii. doi:10.1016/j.otc.2010.01.002. PMC 2879398. PMID 20510711.
  2. Jena A, Patnayak R, Prakash J, Sachan A, Suresh V, Lakshmi AY (2015). "Malignancy in solitary thyroid nodule: A clinicoradiopathological evaluation". Indian J Endocrinol Metab. 19 (4): 498–503. doi:10.4103/2230-8210.159056. PMC 4481656. PMID 26180765.
  3. Chibishev A, Simonovska N, Shikole A (2010). "Post-corrosive injuries of upper gastrointestinal tract". Prilozi. 31 (1): 297–316. PMID 20693948.
  4. Bomeli SR, LeBeau SO, Ferris RL (2010). "Evaluation of a thyroid nodule". Otolaryngol. Clin. North Am. 43 (2): 229–38, vii. doi:10.1016/j.otc.2010.01.002. PMC 2879398. PMID 20510711.
  5. Jena A, Patnayak R, Prakash J, Sachan A, Suresh V, Lakshmi AY (2015). "Malignancy in solitary thyroid nodule: A clinicoradiopathological evaluation". Indian J Endocrinol Metab. 19 (4): 498–503. doi:10.4103/2230-8210.159056. PMC 4481656. PMID 26180765.
  6. Chibishev A, Simonovska N, Shikole A (2010). "Post-corrosive injuries of upper gastrointestinal tract". Prilozi. 31 (1): 297–316. PMID 20693948.